Thiazolidinedione Treatment Prevents Free Fatty Acid-Induced Insulin Resistance in Male Wistar Rats

Diabetes

Volumn 50, Issue 10, 2001, Pages 2316-2322

  Hevener, Andrea L ^a   Reichart, Donna ^b   Janez, Andrej ^a   Olefsky, Jerrold ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CD36 ANTIGEN; CELL RECEPTOR; CHROMAN DERIVATIVE; FATTY ACID; GLUCOSE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; LIGAND; LIPID EMULSION; LIPOSYN; MEMBRANE PROTEIN; ORGANIC ANION TRANSPORTER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; TROGLITAZONE; TYROSINE;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; RAT; SKELETAL MUSCLE; WISTAR RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD36; CHROMANS; FAT EMULSIONS, INTRAVENOUS; FATTY ACIDS, NONESTERIFIED; GLUCOSE; INSULIN; INSULIN RESISTANCE; LIGANDS; LIVER; MALE; MEMBRANE GLYCOPROTEINS; MUSCLE, SKELETAL; ORGANIC ANION TRANSPORTERS; PHOSPHOPROTEINS; PHOSPHORYLATION; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TYROSINE;

EID: 0035490909     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.10.2316     Document Type: Article

References (41)

1. Chakley SM, Hettiarachehi M, Chisholm DJ, Kraegen EW: Five-hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 47:1121-1126, 1998
2. Boden G, Chen X, Ruiz J, White JV, Rossetti L: Mechanism of fatty acid induced inhibition of glucose uptake. J Clin Invest 93:2438-2446, 1994
3. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259, 1999
4. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-D: Measurement of plasma glucose, free fatty acid, lactate and insulin for 24 hours in patients with NIDDM. Diabetes 37:1020-1024, 1988
5. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992
6. Nolte LA, Galuska D, Martin IK, Zierath JR, Wallberg-Henriksson H: Elevated free fatty acid levels inhibit glucose phosphorylation in slow-twitch rat skeletal muscle. Acta Physiol Scand 151:51-59, 1994
7. Roden M, Price TB, Perseghin G, Falk Peterson K, Rothman D, Cline GW, Shulman GI: Mechanisms of free fatty-acid induced insulin resistance in humans. J Clin Invest 97:2859-2865, 1996
8. Saltiel AR, Olefsky JO: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
9. Hofmann C, Lorenz K, Colca JR: Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129:1915-1925, 1991
10. Lee MK, Miles PDG, Khoursheed M, Goa KM, Moossa AR, Olefsky JM: Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Metabolism 43:1435-1439, 1994
11. Miles PDG, Romero OM, Higo K, Cohen A, Rafaat K, Olefsky JM: TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46:1678-1683, 1997
12. Peraldi P, Xu M, Spiegelman BM: Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869, 1997
13. Sizer KM, Smith CL, Jacob CS, Swanson ML, Bleasdale JE: Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism. Mol Cell Endocrinol 103(1-2):1-12, 1994
14. Kemnitz JW, Elson DF, Roechner EB, Baum ST, Bergman RN, Meglasson M: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin and lipid levels, and lowers blood pressure in obese insulin resistant rhesus monkeys. Diabetes 43:204-211, 1994
15. Kelley DE, Goodpaster B, Wing RR, Simoneau JA: Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 277:E1130-E1141, 1999
16. Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T: Differential activation of peroxisome proliferator-activated receptor-γ by Troglitazone and Rosiglitazone. Diabetes 49:539-547, 2000
17. Janez A, Worrall DS, Olefsky JM: Insulin-mediated cellular insulin resistance decreases osmotic shock-induced glucose transport in 3T3-L1 adipocytes. Endocrinology 141:4657-4663, 2000
18. Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
19. Lillioja S, Bogardus C, Mott D, Kennedy A, Knowler W, Howard B: Relationship between insulin-stimulated glucose disposal and lipid metabolism in man. J Clin Invest 75:1106-1115, 1985
20. Rebrin K, Steil GM, Mittelman SD, Bergman RN: Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest 98:741-749, 1996
21. Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller DE: Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPAR γ agonist) action. Endocrinology 139:5034-5041, 1998
22. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274, 1999
23. Kanoh Y, Bandyopadhyay G, Sanjan MP, Standaert ML, Farese RV: Thiazolidindione treatment enhances insulin effects on protein kinase C-ζ/λ activation and glucose transport in adipocytes on nondiabetic and Goto-Kakizaki Type II diabetic rats. J Biol Chem 275:16690-16696, 2000
24. Jucker BM, Rennings AJM, Cline GW, Shulman GI: 13C and 31P NMR studies on the effects of increased plasma free fatty acids and intramuscular glucose metabolism in the awake rat. J Biol Chem 272:10464-10473, 1997
25. Randle PJ, Garland PB, Newsholme EA, Hales CN: The glucose fatty-acid cycle: the role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Ann N Y Acad Sci 131:324-333, 1965
26. Storlien LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S, Kraegen EW: Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipids. Diabetes 40:280-289, 1991
27. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus BC, Jenkins AB, Storlien LH: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983-988, 1997
28. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of a new and antidiabetic agent, CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1849-1888, 1988
29. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953-12956, 1995
30. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity thiazolidinediones. J Med Chem 39:665-668, 1996
31. Braissant O, Foufelle F, Scott C, Dauce M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distributions of PPAR-α, β and γ in adult rat. Endocrinology 137:354-366, 1996
32. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, Werman A, Pories WJ, Caro JF, Flier JS: Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99:2416-2422, 1997
33. Abumrad N, Harmon C, Ibrahimi A: Membrane transport of long-chain fatty acids: evidence for a facilitated process. J Lipid Res 39:2309-2318, 1998
34. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Xin L, Zhong K, Cameron R, Abumrad NA: Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274:26761-26766, 1999
35. Tontonoz P, Hu E, Spiegelman BM: Regulation of adipocyte gene expression and differentiation by PPAR γ2, a lipid activated transcription factor. Cell 79:1147-1156, 1994
36. Kletzien RF, Clarke SD, Ulrich RG: Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393-398, 1992
37. Ide T, Nakazawa T, Mochizuki T, Murakami K: Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 49:521-525, 2000
38. Nisoli E, Carruba MO, Tonello C, Macor C, Federspil G, Vettor R: Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor γ2, leptin, uncoupling protein 2 and 3, and tumor necrosis factor-α gene expression in human subcutaneous fat by lipid infusion. Diabetes 49:319-324, 2000
39. Tontonoz P, Nagy L, Alvarez JGA, Thomszy VA, Evans RM: PPAR γ promoter monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
40. Furler SM, Cooney GJ, Hegarty BD, Lim-Fraser MY, Kraegen EW, Oakes ND: Local factors modulate tissue-specific NEFA utilization. Diabetes 49:1427-1433, 2000
41. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SFA, Silverstein RL: A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 274:19055-19062, 1999